Teri is a research fellow at the Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology. She has studied mathematics at Harvey Mudd College and computational neuroscience at Boston University, and she has been a visiting researcher at Harvard Medical School. Funded by the Research Council of Norway, Teri has published a meta-analysis of randomized controlled trials of LSD for alcoholism, showing a sustained beneficial effect following a single dose of LSD (an independent assessment for the UK NHS reported, “The review was generally well conducted and the authors’ cautious conclusions are likely to be reliable”), a large population study of mental health in people who have used psychedelics, showing that psychedelic use does not appear to increase mental health problems and may even improve mental health, and a neurobiological rationale for using MDMA to augment exposure therapy for anxiety disorders. Teri’s research has been featured in Nature News, BBC World News, Scientific American, and many other media sources. Teri is board leader of EmmaSofia, a non-profit organization based in Oslo, Norway, working to increase access to quality-controlled MDMA and psychedelics
TITLE: Risk assessment and risk communication
Prohibition of non-medical use of psilocybin, LSD, and other psychedelics was based on case reports and worst-case scenarios, rather than objective, evidence-based assessment of the risk of harm per user. Today, the expert consensus is that psilocybin and LSD are much less harmful than alcohol to the individual user. How can we communicate about risk to the general public, to courts, and to policy makers? I will present evidence from the Netherlands and the US on risks of psilocybin and LSD, share insights from the fields of risk assessment and risk communication, and answer some common questions about risk of psychedelics.